Skip to main content
. Author manuscript; available in PMC: 2010 Apr 28.
Published in final edited form as: Sci Transl Med. 2010 Feb 3;2(17):17ra10. doi: 10.1126/scitranslmed.3000116

Figure 3. Administration of sc28AT and Tacrolimus prevents kidney allograft rejection in baboons.

Figure 3

(A) Rejection-free survival after renal allotransplantation for baboons without therapy (n=3) or treated with a 25 day induction therapy with sc28AT alone (n=4), Tacrolimus for 90 days (n=4) and sc28AT + Tacrolimus (25 and 90 days, respectively; n=5). Vertical hash marks, death of recipients without graft rejection as assessed by histology. White square, remaining living baboon. **, P=0.008 versus Tacrolimus monotherapy. ##, P=0.01 versus untreated controls. (B) Total lymphocyte counts (means ± SD, upper panel) and CD3+ T cell counts (lower panel) in untreated recipients (n=3) and recipients treated with sc28AT monotherapy (n=4). (C) Phenotype of blood T cells during the first week post transplantation in controls (n=3; left panel) and sc28AT monotherapy recipients (n=4; right panel). Percentages of T cells expressing the specified marker on day 0, 1, 2, 4 and 6 from left (black) to right (white). *, P<0.05. (D) Donor-specific hyporesponsiveness. PBMC were harvested from baboons in the sc28AT + Tacrolimus group and tested in MLR against donor cells before transplantation (black bars) and at day 90 (white bars) and against 3rd party cells at day 90 (grey bars). Results are mean stimulatory index ± SD of triplicate wells. Two experiments are shown. **, P=0.0014.